Phase 1 clinical trial of a monoclonal antibody against the chikungunya virus
Concussion linked to short- and long-term risk for overall health
5 March 2021Controlling adhesions in the abdomen
5 March 2021Phase 1 clinical trial of a monoclonal antibody against the chikungunya virus
Evotec, a drug company headquartered in Hamburg, Germany, has begun a phase 1 clinical trial of a monoclonal antibody against the chikungunya virus that was identified at Vanderbilt University Medical Center.
